175 related articles for article (PubMed ID: 15673766)
1. Interspecies recombination in type II topoisomerase genes is not a major cause of fluoroquinolone resistance in invasive Streptococcus pneumoniae isolates in the United States.
Pletz MW; McGee L; Beall B; Whitney CG; Klugman KP
Antimicrob Agents Chemother; 2005 Feb; 49(2):779-80. PubMed ID: 15673766
[TBL] [Abstract][Full Text] [Related]
2. Stability of fluoroquinolone resistance in Streptococcus pneumoniae clinical isolates and laboratory-derived mutants.
Smith-Adam HJ; Nichol KA; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2005 Feb; 49(2):846-8. PubMed ID: 15673786
[TBL] [Abstract][Full Text] [Related]
3. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.
Richter SS; Heilmann KP; Beekmann SE; Miller NJ; Rice CL; Doern GV
Clin Infect Dis; 2005 Jan; 40(2):225-35. PubMed ID: 15655739
[TBL] [Abstract][Full Text] [Related]
4. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine.
Pletz MW; McGee L; Jorgensen J; Beall B; Facklam RR; Whitney CG; Klugman KP
Antimicrob Agents Chemother; 2004 Sep; 48(9):3491-7. PubMed ID: 15328116
[TBL] [Abstract][Full Text] [Related]
5. Longitudinally tracking fluoroquinolone resistance and its determinants in penicillin-susceptible and -nonsusceptible Streptococcus pneumoniae isolates in Hong Kong, 2000 to 2005.
Ip M; Chau SS; Chi F; Cheuk ES; Ma H; Lai RW; Chan PK
Antimicrob Agents Chemother; 2007 Jun; 51(6):2192-4. PubMed ID: 17371818
[TBL] [Abstract][Full Text] [Related]
6. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG
J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
[TBL] [Abstract][Full Text] [Related]
7. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004).
Deshpande LM; Sader HS; Debbia E; Nicoletti G; Fadda G; Jones RN;
Diagn Microbiol Infect Dis; 2006 Mar; 54(3):157-64. PubMed ID: 16423493
[TBL] [Abstract][Full Text] [Related]
8. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.
Fuller JD; Low DE
Clin Infect Dis; 2005 Jul; 41(1):118-21. PubMed ID: 15937772
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Jones RN; Fritsche TR; Sader HS
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
[TBL] [Abstract][Full Text] [Related]
10. In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease.
Pérez-Trallero E; Marimón JM; González A; Ercibengoa M; Larruskain J
Clin Infect Dis; 2005 Aug; 41(4):560-4. PubMed ID: 16028169
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?
Doern GV; Richter SS; Miller A; Miller N; Rice C; Heilmann K; Beekmann S
Clin Infect Dis; 2005 Jul; 41(2):139-48. PubMed ID: 15983908
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
Lister PD
Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
[TBL] [Abstract][Full Text] [Related]
14. Resistance of Streptococcus pneumoniae to fluoroquinolones--United States, 1995-1999.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Sep; 50(37):800-4. PubMed ID: 11785571
[TBL] [Abstract][Full Text] [Related]
15. Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae.
Schurek KN; Adam HJ; Hoban DJ; Zhanel GG
Int J Antimicrob Agents; 2006 Sep; 28(3):266-9. PubMed ID: 16904294
[TBL] [Abstract][Full Text] [Related]
16. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).
Davies TA; Yee YC; Goldschmidt R; Bush K; Sahm DF; Evangelista A
J Antimicrob Chemother; 2006 Mar; 57(3):437-42. PubMed ID: 16431861
[TBL] [Abstract][Full Text] [Related]
17. TARGETed surveillance: susceptibility of Streptococcus pneumoniae isolated from community-acquired respiratory tract infections in 2003 to fluoroquinolones and other agents.
Morrissey I; Colclough A; Northwood J
Int J Antimicrob Agents; 2007 Oct; 30(4):345-51. PubMed ID: 17643269
[TBL] [Abstract][Full Text] [Related]
18. Decline in the prevalence of pandemic clones Spain23F-1 and Spain9V-3 among US fluoroquinolone-resistant Streptococcus pneumoniae TRUST Surveillance isolates since 2001.
Davies TA; Yee YC; Goldschmidt R; Sahm DF; Evangelista AT
Postgrad Med; 2008 Sep; 120(3 Suppl 1):39-45. PubMed ID: 18931470
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates of Streptococcus pneumoniae in the United States.
Pletz MW; Shergill AP; McGee L; Beall B; Whitney CG; Klugman KP;
Antimicrob Agents Chemother; 2006 Apr; 50(4):1561-3. PubMed ID: 16569885
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates.
Adam HJ; Schurek KN; Decorby MR; Weshnoweski B; Vashisht R; Karlowsky K; Hoban DJ; Zhanel GG
J Antimicrob Chemother; 2006 Jul; 58(1):202-4. PubMed ID: 16636082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
